Evidence map›Paper›PMID 40278841›Full record

Trial reportCancer2025

Impact of resistance training on inflammatory biomarkers and associations with treatment outcomes in colon cancer.

Seohyuk Lee, Chao Ma, Bette J Caan, Alexandra M Binder, Justin C Brown, Amalia Pena Perez, Catherine Lee, Erin Weltzien, Michelle C Ross, Charles P Quesenberry and 5 more

Registry-linked trialAbstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03291951 (FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03291951 nacompletednot on this map

FOcus on Reducing Dose-limiting Toxicities in Colon Cancer With Resistance Exercise Study

TypeinterventionalSponsorKaiser PermanenteRan2018 to 2022Enrolled183ConditionsResistance Training, Colon Cancer, Chemotherapy EffectArmsResistance training
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Seohyuk LeeDepartment of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Chao MaDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Bette J CaanDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.ORCID https://orcid.org/0000-0002-5803-310X
Alexandra M BinderCancer Epidemiology, University of Hawaii Cancer Center, Honolulu, Hawaii, USA.
Justin C BrownCancer Metabolism Program, Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.ORCID https://orcid.org/0000-0002-0602-3284
Amalia Pena PerezDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Catherine LeeDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Erin WeltzienDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Michelle C RossDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Charles P QuesenberryDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Kristin L CampbellDepartment of Physical Therapy, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.ORCID https://orcid.org/0000-0002-2266-1382
Elizabeth M Cespedes FelicianoDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.ORCID https://orcid.org/0000-0003-1192-4017
Adrienne CastilloDivision of Research, Kaiser Permanente Northern California, Pleasanton, California, USA.
Kathryn H SchmitzDivision of Hematology and Oncology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID https://orcid.org/0000-0003-2400-2935
Jeffrey A MeyerhardtDivision of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

Funding

Resistance Training to Reduce Chemotoxicity in Colon CancerR01CA206196 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI CAAN, BETTE J, MEYERHARDT, JEFFREY A · 2017 to 2021
$4.1M
D3-creatine dilution to determine skeletal muscle mass in colon cancer patientsR01CA240394 · NCI · KAISER FOUNDATION RESEARCH INSTITUTE · PI FELICIANO, ELIZABETH MARJORIE CESPEDES · 2020 to 2023
$1.5M
NCI NIH HHS R01 CA206196NCI NIH HHS R01CA206196NCI NIH HHS R01 CA240394
6 · The paper itself

Abstract

introductionAmong patients with colon cancer undergoing adjuvant chemotherapy, the impact of resistance training with supplemental dietary protein on inflammatory changes during treatment, whether baseline or changes in inflammatory markers are associated with relative dose intensity (RDI), and the associations of inflammation with body composition were investigated.

methodsA multicenter randomized clinical trial of 174 patients with colon cancer undergoing adjuvant chemotherapy assigned to a home-based resistance training program or usual care was conducted. High-sensitivity C-reactive protein (hsCRP), interleukin-6, tumor necrosis factor-α receptor-II, and growth differentiation factor-15 levels were assessed preintervention and following chemotherapy completion. Baseline body composition was evaluated via dual-energy X-ray absorptiometry. Multivariate analyses were adjusted for sociodemographic and clinical factors.

resultsPatients randomized to resistance training versus usual care experienced similar changes in all inflammatory markers. Those in the highest versus lowest tertile of baseline hsCRP were more likely to have received RDI >70% (odds ratio, 4.11; 95% CI, 1.29-13.1); however, changes across any of the inflammatory markers were not associated with RDI. Patients in the highest versus lowest tertiles of hsCRP, interleukin-6, and tumor necrosis factor-α receptor-II were more likely to have higher baseline body mass index, total lean mass, and total fat mass.

conclusionInflammatory markers in patients with colon cancer undergoing adjuvant chemotherapy were not significantly impacted by randomization to a resistance training program but were associated with baseline body composition measures. Further investigations are needed to better elucidate the potential role of inflammatory markers and body composition in predicting important treatment outcomes. CLINICALTRIALS: GOV: NCT03291951.

Indexed as

Colonic NeoplasmsInflammationResistance TrainingAgedBiomarkersBiomarkers, TumorBody CompositionChemotherapy, AdjuvantC-Reactive ProteinFemaleHumansInterleukin-6MaleMiddle AgedReceptors, Tumor Necrosis Factor, Type IITreatment OutcomeBiomarkersBiomarkers, TumorC-Reactive ProteinInterleukin-6Receptors, Tumor Necrosis Factor, Type IIbody compositioninflammatory biomarkerrelative dose intensityresistance training

Identifiers

PMID40278841
PMCPMC12121940

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.